G1 Therapeutics, Inc.
DelistedCIK 1560241fmd_1HCQZCS00X5F0VA1AQHDXZREZ7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Jun 30, 2024, 35 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 45 | 31 | 51 | 83 |
| Research and development | 13 | 25 | 54 | 71 | 89 | 73 | 76 | 83 | 44 |
| Selling, general and administrative | – | – | – | – | 40 | 68 | 96 | 100 | 71 |
| Total operating expenses | 16 | 30 | 61 | 89 | 129 | 142 | 174 | 187 | 122 |
| Operating income | (15) | (30) | (61) | (89) | (129) | (96) | (142) | (136) | (40) |
| Other non-operating income (expense) | (5) | 0 | 1 | 4 | 7 | (1) | (5) | (10) | (5) |
| Income before taxes | – | – | – | (85) | (122) | (98) | (147) | (146) | (45) |
| Income tax expense | – | – | – | – | – | 1 | 1 | 2 | 3 |
| Net income from continuing operations | – | – | – | – | – | (99) | (148) | (148) | (48) |
| Net income | (20) | (30) | (60) | (85) | (122) | (99) | (148) | (148) | (48) |
| Net income to common shareholders | (22) | (35) | (65) | (85) | (122) | – | – | – | – |